Always appreciate your technical analysis, so thanks for posting (also, you might head over to Investor Village to post as well - would welcome that).
You are saying that an upgrade is not the impetus for the recent moves. However, I don't think the argument is that it's the analyst announcement per se but some positive PII/III Tardive Dyskenisia news from TEVA (acquirer of ASPX), whose drug has the same mechanism of action as NBIX's drug, that is the reason for the action. Thoughts?
The research release may have gotten the ball rolling, but in my opinion, it did so because the technicals let it. Amongus is/was right, the chart is terrific and we are breaking out now. We'll see where it goes. The research may have put it over the edge, but I don't think it's the main mover. It's not like "better mouse trap" wasn't already known (I knew it and who the heck am I?).
That said, it's a bit of "angels on the head of a pin" discussion maybe. I'm just thankful for the breakout. And appreciate posts by all in this thread.